Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Thalidomide in Hormone-Refractory Prostate Cancer
NCT00001446Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Sep 1995
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of thalidomide in prostate cancer (PCa) (2 arms), sponsored by National Cancer Institute. Primary endpoint: Prostate-Specific Antigen Response. Started Sep 1995; status: completed.
02
Drugs
thalidomide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT00001446.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00001446.